P2RX4

Across TCGA pan-cancer cohorts, P2RX4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated P2RX4 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher P2RX4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated P2RX4 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where P2RX4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.295	0.494	.005	31	view →
COAD	DFS	Tertile	All	0.914	1.000	.035	6	view →
CCRCC	DFS	Quartile	All	0.650	0.884	.030	5	view →
LUAD	OS	Median	II,III,IV	0.891	0.455	.035	2	view →
LSCC	OS	Quartile	II,III,IV	0.655	0.927	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

P2RX4–PDAC (DFS)

Open the PDAC breakdown →